0 CHECKOUT

Obsessive-Compulsive Disorder - Pipeline Review, H2 2015

  • ID: 3404588
  • July 2015
  • 58 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • C4X Discovery Limited
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Omeros Corporation
  • MORE

Obsessive-Compulsive Disorder - Pipeline Review, H2 2015

Summary

The report ‘Obsessive-Compulsive Disorder - Pipeline Review, H2 2015’, provides an overview of the Obsessive-Compulsive Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • C4X Discovery Limited
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Omeros Corporation
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Obsessive-Compulsive Disorder Overview

Therapeutics Development

Pipeline Products for Obsessive-Compulsive Disorder - Overview

Pipeline Products for Obsessive-Compulsive Disorder - Comparative Analysis

Obsessive-Compulsive Disorder - Therapeutics under Development by Companies

Obsessive-Compulsive Disorder - Therapeutics under Investigation by Universities/Institutes

Obsessive-Compulsive Disorder - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Obsessive-Compulsive Disorder - Products under Development by Companies

Obsessive-Compulsive Disorder - Products under Investigation by Universities/Institutes

Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development

AbbVie Inc.

Addex Therapeutics Ltd

C4X Discovery Limited

F. Hoffmann-La Roche Ltd.

Novartis AG

Omeros Corporation

Rottapharm SpA

Sellas Inc.

Obsessive-Compulsive Disorder - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ADX-71743 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADX-88178 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bitopertin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CR-5542 Series - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dipraglurant IR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fluvoxamine maleate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mavoglurant - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Methoxycoronaridine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

zolpidem tartrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Obsessive-Compulsive Disorder - Recent Pipeline Updates

Obsessive-Compulsive Disorder - Dormant Projects

Obsessive-Compulsive Disorder - Discontinued Products

Obsessive-Compulsive Disorder - Product Development Milestones

Featured News & Press Releases

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Obsessive-Compulsive Disorder, H2 2015

Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H2 2015

Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H2 2015

Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Limited, H2 2015

Obsessive-Compulsive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H2 2015

Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H2 2015

Obsessive-Compulsive Disorder - Pipeline by Rottapharm SpA, H2 2015

Obsessive-Compulsive Disorder - Pipeline by Sellas Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Obsessive-Compulsive Disorder Therapeutics - Recent Pipeline Updates, H2 2015

Obsessive-Compulsive Disorder - Dormant Projects, H2 2015

Obsessive-Compulsive Disorder - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Obsessive-Compulsive Disorder, H2 2015

Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
Addex Therapeutics Ltd
C4X Discovery Limited
F. Hoffmann-La Roche Ltd.
Novartis AG
Omeros Corporation
Rottapharm SpA
Sellas Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S